Non-Invasive Monitoring Systems, Inc. is a medical technology company that previously focused on the development, manufacture, and marketing of noninvasive whole body periodic acceleration therapeutic platforms. The company’s core product was a motorized platform designed to move a subject repetitively from head to foot, thereby delivering a form of mechanical therapy intended to improve circulation and muscle activation. Following the discontinuation of its operations in May 2019, the company no longer manufactures or sells its platforms and has shifted its focus to evaluating potential mergers, acquisitions, and strategic collaborations. As of the latest reporting period, Non-Invasive Monitoring Systems, Inc. remains a shell entity with minimal operational activity. As of October 31, 2025, the company reported a shareholders’ deficit of $989,000 and negative working capital of approximately the same amount, reflecting its limited financial resources.

Prior to discontinuing operations in May 2019, Non-Invasive Monitoring Systems, Inc. generated revenue primarily through the sale and lease of its whole body periodic acceleration platforms to hospitals, rehabilitation centers, and long term care facilities. The company also offered related service and maintenance agreements that contributed to its income stream. Since the cessation of operations, the firm has reported no revenue and relies on external financing, such as proceeds from private equity placements and promissory notes issued to related parties, to cover its ongoing administrative expenses. The company’s operations have been primarily financed through private sales of its equity securities and advances under promissory notes. At October 31, 2025, the company held only $6,000 in cash and faced a working capital deficit of approximately $989,000, underscoring the absence of operational income.

Before its discontinuation, Non-Invasive Monitoring Systems, Inc. occupied a specialized niche within the broader medical device industry, focusing on noninvasive mechanical therapy solutions. Its whole body periodic acceleration platform distinguished itself from conventional pharmacological treatments and invasive surgical procedures by offering a purely physical approach to patient care. The company competed with other manufacturers of motorized rehabilitation equipment, alternative therapy devices, and firms providing electrical stimulation or ultrasound therapy. Its proprietary technology represented a competitive advantage because it required no implants or drugs and could be administered in a variety of clinical settings. Although the firm is no longer active, its intellectual property remains a potential asset for future partners interested in noninvasive modality development. The business faces significant hurdles, including a history of losses, an accumulated deficit, dependence on key management personnel, and the ongoing need for additional external financing to sustain any future efforts.

The company previously served a diverse clientele that included acute care hospitals, subacute rehabilitation centers, veterans medical facilities, and long term care institutions seeking noninvasive options for patient mobility and circulation improvement. While the filing does not disclose individual customer names, it indicates that the firm’s platforms were utilized in settings where rehabilitation and therapeutic mobility were priorities. These customers valued the noninvasive nature of the technology as a complement to conventional physical therapy regimens.